Torrent Pharmaceuticals Limited — Q2FY27 earnings call summary

Filed 29 October 2026 · Official transcript

Cost synergies ahead of plan; INR450 Cr target likely achieved by FY28
Q2 FY27 consolidated revenue 4,979 Cr (+51%), EBITDA 1,666 Cr (+54%), margin 33.5%
US filings increased; 9-10 products expected this fiscal year
IPM growth strong at 12% in H1 FY27, expected to sustain near 10% next year
Semaglutide India market share 32%, supply restored after disruption
JB merger integration caused transient revenue impact; JB India branded +7%, international -7%
Torrent base India business +20%, Brazil +38%, US generics +24%, Germany -7%
R&D spend increased to 4.2% of revenue, sustained for 2-3 years